For research use only. Not for therapeutic Use.
The first, non-nucleoside adenosine kinase (ADK) inhibitor (IC50 value 2 nM and 50 nM in cytosolic and intact cell assays, respectively). ABT702 is orally active to reduce pain and inflammation in animal models, yet found to be clastogenic in an in vitro Chinese Hamster micronucleus assay.
KEYWORDS: ABT 702 | supplier | ADK inhibitor | ABT702 | CAS [214697-26-4] | ATP | ADK | pain | inflammation | clastogenic | mutagenesis
| Catalog Number | I012851 |
| CAS Number | 214697-26-4 |
| Molecular Formula | C22H19BrN6O |
| Purity | ≥95% |
| IUPAC Name | 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride |
| InChI | InChI=1S/C22H19BrN6O.2ClH/c23-16-3-1-2-14(10-16)17-11-18(28-22-20(17)21(24)26-13-27-22)15-4-5-19(25-12-15)29-6-8-30-9-7-29;;/h1-5,10-13H,6-9H2,(H2,24,26,27,28);2*1H |
| SMILES | C1COCCN1C2=NC=C(C=C2)C3=NC4=NC=NC(=C4C(=C3)C5=CC(=CC=C5)Br)N.Cl.Cl |
| Reference | C.H. Lee et al. Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor. J Med Chem. 2001 Jun 21;44(13):2133-8.
P.J. Hajduk et al. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J Med Chem. 2000 Dec 14;43(25):4781-6.
M.F. Jarvis et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory… J Pharmacol Exp Ther. 2000 Dec;295(3):1156-64.
E.A. Kowaluk et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory… J Pharmacol Exp Ther. 2000 Dec;295(3):1165-74. |
